In this study, we present the results of nitrogen deposition on land from a set of 29 simulations from six different tropospheric chemistry models pertaining to present‐day and 2100 conditions. ...Nitrogen deposition refers here to the deposition (wet and dry) of all nitrogen‐containing gas phase chemical species resulting from NOx (NO + NO2) emissions. We show that under the assumed IPCC SRES A2 scenario the global annual average nitrogen deposition over land is expected to increase by a factor of ∼2.5, mostly because of the increase in nitrogen emissions. This will significantly expand the areas with annual average deposition exceeding 1 gN/m2/year. Using the results from all models, we have documented the strong linear relationship between models on the fraction of the nitrogen emissions that is deposited, regardless of the emissions (present day or 2100). On average, approximately 70% of the emitted nitrogen is deposited over the landmasses. For present‐day conditions the results from this study suggest that the deposition over land ranges between 25 and 40 Tg(N)/year. By 2100, under the A2 scenario, the deposition over the continents is expected to range between 60 and 100 Tg(N)/year. Over forests the deposition is expected to increase from 10 Tg(N)/year to 20 Tg(N)/year. In 2100 the nitrogen deposition changes from changes in the climate account for much less than the changes from increased nitrogen emissions.
We present far-infrared (FIR) analysis of 68 brightest cluster galaxies (BCGs) at 0.08 < z < 1.0. Deriving total infrared luminosities directly from Spitzer and Herschel photometry spanning the peak ...of the dust component (24-500 mu m), we calculate the obscured star formation rate (SFR). 22 super(+6.2) sub(-5.3)% of the BCGs are detected in the far-infrared, with SFR = 1-150 M sub(middot in circle) yr super(-1). The infrared luminosity is highly correlated with cluster X-ray gas cooling times for cool-core clusters (gas cooling time <1 Gyr), strongly suggesting that the star formation in these BCGs is influenced by the cluster-scale cooling process. The occurrence of the molecular gas tracing H alpha emission is also correlated with obscured star formation. For all but the most luminous BCGs (L sub(TIR) > 2 x 10 super(11) L sub(middot in circle)), only a small (<, ~0.4 mag) reddening correction is required for SFR(H alpha ) to agree with SFR sub(FIR). The relatively low H alpha extinction (dust obscuration), compared to values reported for the general star-forming population, lends further weight to an alternate (external) origin for the cold gas. Finally, we use a stacking analysis of non-cool-core clusters to show that the majority of the fuel for star formation in the FIR-bright BCGs is unlikely to originate from normal stellar mass loss.
Recent evidence suggests that the duration of protection by bacillus Calmette-Guérin (BCG) may exceed previous estimates with potential implications for estimating clinical and cost-efficacy.
To ...estimate the protection and duration of protection provided by BCG vaccination against tuberculosis, explore how this protection changes with time since vaccination, and examine the reasons behind the variation in protection and the rate of waning of protection.
Electronic databases including MEDLINE, Excerpta Medica Database (EMBASE), Cochrane Databases, NHS Economic Evaluation Database (NHS EED), Database of Abstracts of Reviews of Effects (DARE), Web of Knowledge, Biosciences Information Service (BIOSIS), Latin American and Caribbean Health Sciences Literature (LILACs), MEDCARIB Database, Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched from inception to May 2009. Index to Theses, System for Information on Grey Literature in Europe (SIGLE), Centre for Agricultural Bioscience International (CABI) Abstracts, Scopus, Article First, Academic Complete, Africa-Wide Information, Google Scholar, Global Health, British National Bibliography for Report Literature, and clinical trial registration websites were searched from inception to October 2009.
Electronic databases searches, screening of identified studies, data extraction and analysis were undertaken. Meta-analysis was used to present numerical and graphical summaries of clinical efficacy and efficacy by time since vaccination. Evidence of heterogeneity was assessed using the tau-squared statistic. Meta-regression allowed the investigation of observed heterogeneity. Factors investigated included BCG strain, latitude, stringency of pre-BCG vaccination tuberculin testing, age at vaccination, site of disease, study design and vulnerability to biases. Rate of waning of protection was estimated using the ratio of the measure of efficacy after 10 years compared with the efficacy in the first 10 years of a study.
Study selection. A total of 21,030 references were identified, providing data on 132 studies after abstract and full-text review. Efficacy. Protection against pulmonary tuberculosis in adults is variable, ranging from substantial protection in the UK MRC trial {rate ratio 0.22 95% confidence interval (CI) 0.16 to 0.31}, to absence of clinically important benefit, as in the large Chingleput trial rate ratio 1.05 (95% CI 0.88 to 1.25) and greater in latitudes further away from the equator. BCG vaccination efficacy was usually high, and varied little by form of disease (with higher protection against meningeal and miliary tuberculosis) or study design when BCG vaccination was given only to infants or to children after strict screening for tuberculin sensitivity. High levels of protection against death were observed from both trials and observational studies. The observed protective effect of BCG vaccination did not differ by the strain of BCG vaccine used in trials.
Reviewed studies showed that BCG vaccination protects against pulmonary and extrapulmonary tuberculosis for up to 10 years. Most studies either did not follow up participants for long enough or had very few cases after 15 years. This should not be taken to indicate an absence of effect: five studies (one trial and four observational studies) provided evidence of measurable protection at least 15 years after vaccination. Efficacy declined with time. The rate of decline was variable, with faster decline in latitudes further from the equator and in situations where BCG vaccination was given to tuberculin-sensitive participants after stringent tuberculin testing.
The main limitation of this review relates to quality of included trials, most of which were conducted before current standards for reporting were formulated. In addition, data were lacking in some areas and the review had to rely on evidence from observational studies.
BCG vaccination protection against tuberculosis varies between populations, to an extent that cannot be attributed to chance alone. Failure to exclude those already sensitised to mycobacteria and study latitude closer to the equator were associated with lower efficacy. These factors explained most of the observed variation. There is good evidence that BCG vaccination protection declines with time and that protection can last for up to 10 years. Data on protection beyond 15 years are limited; however, a small number of trials and observational studies suggest that BCG vaccination may protect for longer. Further studies are required to investigate the duration of protection by BCG vaccination.
The National Institute for Health Research Health Technology Assessment programme.
The spectrum of tumours arising in childhood is fundamentally different from that seen in adults, and they are known to be divergent from adult malignancies in terms of cellular origins, ...epidemiology, genetic complexity, driver mutations and underlying mutational processes. Despite the immense knowledge generated through sequencing efforts and functional characterization of identified (epi-)genetic alterations over the past decade, the clinical implications of this knowledge have so far been limited. Novel preclinical platforms such as the European Innovative Therapies for Children with Cancer-Paediatric Preclinical Proof-of-Concept Platform and the US-based Pediatric Preclinical Testing Consortium are being developed to try to change this by aiming to recapitulate the extensive heterogeneity of paediatric tumours and thereby, hopefully, improve the ability to predict clinical benefit. Numerous studies have also been established worldwide to provide patients with access to real-time molecular profiling and the possibility of more precise mechanism-of-action-based treatments. In addition to tumour-intrinsic findings and mechanisms, ongoing studies are investigating features such as the immune microenvironment of paediatric tumours in comparison with adult cancers - currently of very timely clinical relevance. However, there is an ongoing need for rigorous preclinical biomarker and target validation to feed into the next generation of molecularly stratified clinical trials. This Review aims to provide a comprehensive state-of-the-art overview of the molecular landscape of paediatric solid tumours, including their underlying genomic alterations and interactions with the microenvironment, complemented with our current understanding of potential therapeutic vulnerabilities and how these can be preclinically tested using more accurate predictive methods. Finally, we provide an outlook on the challenges and opportunities associated with translating this overwhelming scientific progress into real clinical benefit.
The coexistence of different species of large herbivores (ungulates) in grasslands and savannas has fascinated ecologists for decades. However, changes in climate, land‐use and trophic structure of ...ecosystems increasingly jeopardise the persistence of such diverse assemblages. Body size has been used successfully to explain ungulate niche differentiation with regard to food requirements and predation sensitivity. But this single trait axis insufficiently captures interspecific differences in water requirements and thermoregulatory capacity and thus sensitivity to climate change. Here, we develop a two‐dimensional trait space of body size and minimum dung moisture content that characterises the combined food and water requirements of large herbivores. From this, we predict that increased spatial homogeneity in water availability in drylands reduces the number of ungulate species that will coexist. But we also predict that extreme droughts will cause the larger, water‐dependent grazers as wildebeest, zebra and buffalo–dominant species in savanna ecosystems – to be replaced by smaller, less water‐dependent species. Subsequently, we explore how other constraints such as predation risk and thermoregulation are connected to this two‐dimensional framework. Our novel framework integrates multiple simultaneous stressors for herbivores and yields an extensive set of testable hypotheses about the expected changes in large herbivore community composition following climate change.
Abstract
We present the discovery and extensive follow-up of a remarkable fast-evolving optical transient, AT 2022aedm, detected by the Asteroid Terrestrial impact Last Alert Survey (ATLAS). In the ...ATLAS
o
band, AT 2022aedm exhibited a rise time of 9 ± 1 days, reaching a luminous peak with
M
g
≈ −22 mag. It faded by 2 mag in the
g
band during the next 15 days. These timescales are consistent with other rapidly evolving transients, though the luminosity is extreme. Most surprisingly, the host galaxy is a massive elliptical with negligible current star formation. Radio and X-ray observations rule out a relativistic AT 2018cow–like explosion. A spectrum in the first few days after explosion showed short-lived He
ii
emission resembling young core-collapse supernovae, but obvious broad supernova features never developed; later spectra showed only a fast-cooling continuum and narrow, blueshifted absorption lines, possibly arising in a wind with
v
≈ 2700 km s
−1
. We identify two further transients in the literature (Dougie in particular, as well as AT 2020bot) that share similarities in their luminosities, timescales, color evolution, and largely featureless spectra and propose that these may constitute a new class of transients: luminous fast coolers. All three events occurred in passive galaxies at offsets of ∼4–10 kpc from the nucleus, posing a challenge for progenitor models involving massive stars or black holes. The light curves and spectra appear to be consistent with shock breakout emission, though this mechanism is usually associated with core-collapse supernovae. The encounter of a star with a stellar-mass black hole may provide a promising alternative explanation.
ABSTRACT We present a study of the spatial distribution and kinematics of star-forming galaxies in 30 massive clusters at 0.15 < z < 0.30, combining wide-field Spitzer 24 m and GALEX near-ultraviolet ...imaging with highly complete spectroscopy of cluster members. The fraction (fSF) of star-forming cluster galaxies rises steadily with cluster-centric radius, increasing fivefold by 2r200, but remains well below field values even at 3r200. This suppression of star formation at large radii cannot be reproduced by models in which star formation is quenched in infalling field galaxies only once they pass within r200 of the cluster, but is consistent with some of them being first pre-processed within galaxy groups. Despite the increasing fSF-radius trend, the surface density of star-forming galaxies actually declines steadily with radius, falling ∼15× from the core to 2r200. This requires star formation to survive within recently accreted spirals for 2-3 Gyr to build up the apparent over-density of star-forming galaxies within clusters. The velocity dispersion profile of the star-forming galaxy population shows a sharp peak of 1.44 at 0.3r500, and is 10%-35% higher than that of the inactive cluster members at all cluster-centric radii, while their velocity distribution shows a flat, top-hat profile within r500. All of these results are consistent with star-forming cluster galaxies being an infalling population, but one that must also survive ∼0.5-2 Gyr beyond passing within r200. By comparing the observed distribution of star-forming galaxies in the stacked caustic diagram with predictions from the Millennium simulation, we obtain a best-fit model in which star formation rates decline exponentially on quenching timescales of 1.73 0.25 Gyr upon accretion into the cluster.
Abstract We report direct evidence of pre-processing of the galaxies residing in galaxy groups falling into galaxy clusters drawn from the Local Cluster Substructure Survey (LoCuSS). 34 groups have ...been identified via their X-ray emission in the infall regions of 23 massive (〈M200〉 = 1015 M⊙) clusters at 0.15 < z < 0.3. Highly complete spectroscopic coverage combined with 24 μm imaging from Spitzer allows us to make a consistent and robust selection of cluster and group members including star-forming galaxies down to a stellar mass limit of M⋆ = 2 × 1010 M⊙. The fraction fSF of star-forming galaxies in infalling groups is lower and with a flatter trend with respect to clustercentric radius when compared to the rest of the cluster galaxy population. At R ≈ 1.3 r200, the fraction of star-forming galaxies in infalling groups is half that in the cluster galaxy population. This is direct evidence that star-formation quenching is effective in galaxies already prior to them settling in the cluster potential, and that groups are favourable locations for this process.
...the initial trials comparing COVID-19 vaccines versus placebo should seek reliable evidence not only of some efficacy but of worthwhile efficacy. ...although efficacy far greater than 50% would be ...better, efficacy of about 50% would represent substantial progress. Evaluation of multiple COVID-19 vaccines with standardised methodology will facilitate regulatory and deployment decisions.7 Unless such decisions are informed by reliable randomised evidence, the effect on public acceptance of COVID-19 vaccines could adversely affect COVID-19 control and the uptake of vaccines against other diseases.8 The WHO Solidarity Vaccines Trial9 (figure) aims to evaluate efficiently and rapidly (within 3–6 months of each vaccine's introduction into the study) the efficacy of multiple vaccines,10 helping to ensure that weakly effective vaccines are not deployed.
PDF
